https://doi.org/10.5217/ir.2023.00194 • Intest Res 2024;22(3):369-377

Supplementary Table 4. Patients' Disease Characteristics at the Time of Tofacitinib Reduction

Variable at the time of reduction	Continued 5 mg b.d. tofacitinib (n = 10)	Loss of response (n = 13)	*P*-value
Period to reduction (wk)	13 (9.5–17.5)	17 (9–24)	0.859
Partial Mayo score	0 (0–1)	2 (0–3)	0.349
White blood cells (/μL)	5,700 (4,875–6,525)	4,800 (3,740–5,860)	0.098
Hemoglobin (g/dL)	14.2 (12.6–15.8)	13.6 (12.6–14.6)	0.238
Albumin (g/dL)	4.2 (4.0–4.5)	4.3 (4.0–4.6)	0.437
C-reactive protein (mg/L)	0.3 (0–1.1)	0.2 (0–0.4)	0.170

Values are presented as median (interquartile range). Differences in median between the 2 groups were compared by non-parametric test (Kruskal-Wallis test). We compared patients' disease characteristics at the time of tofacitinib reduction. Patients who responded to tofacitinib treatment at 8 weeks, subsequently reduced tofacitinib to 5 mg b.d. (twice daily), and the comparison study was performed for the patients who continued 5 mg b.d. tofacitinib versus patients who lost response to 5 mg b.d. tofacitinib and underwent 10 mg b.d. tofacitinib retreatment (laboratory data was available in 15 out of 23 patients, 6 were loss of response patients).